Clostridium difficile infection: A critical overview (original) (raw)

• Blossom DB, McDonald LC: The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis 2007, **45:**222–227.
  Article PubMed Google Scholar
• Owens RC Jr, Valenti AJ: Clostridium difficile-associated disease in the new millenium: “the perfect storm” has arrived. Infect Dis Clin Pract 2007, **15:**299–315.
  Article Google Scholar
• Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL: Commentary: Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977; **136:**701. J Infect Dis 2004, 190:202–209.
  PubMed CAS Google Scholar
• Bartlett JG, Moon N, Chang TW, et al.: Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, **75:**778–782.
  PubMed CAS Google Scholar
• Loo VG, Poirier L, Miller MA, et al.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, **353:**2442–2449.
  Article PubMed CAS Google Scholar
• Gerding DN, Johnson S, Peterson LR, et al.: Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995, **16:**459–477.
  PubMed CAS Google Scholar
• Valiquette L, Cossette B, Garant MP, et al.: Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007, **45(Suppl 2):**S112–S121.
  Article PubMed CAS Google Scholar
• Dial S, Delaney JA, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, **294:**2989–2995.
  Article PubMed CAS Google Scholar
• Dial S, Alrasadi K, Manoukian C, et al.: Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, **171:**33–38.
  PubMed Google Scholar
• Kazakova SV, Ware K, Baughman B, et al.: A hospital Outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006, **166:**2518–2524.
  Article PubMed Google Scholar
• McFarland LV, Beneda HW, Clarridge JE, Raugi GJ: Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007, **35:**237–253.
  Article PubMed Google Scholar
• Johal SS, Lambert CP, Hammond J, et al.: Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J Clin Pathol 2004, **57:**973–979.
  Article PubMed CAS Google Scholar
• Mulligan ME, Miller SD, McFarland LV, et al.: Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993, **16(Suppl 4):**S239–S244.
  PubMed Google Scholar
• Muto CA, Pokrywka M, Shutt K, et al.: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, **26:**273–280.
  Article PubMed Google Scholar
• Johnson S, Gerding DN: Clostridium difficile-associated diarrhea. Clin Infect Dis 1998, **26:**1027–1034.
  Article PubMed CAS Google Scholar
• Owens RC: Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs 2007, **67:**487–502.
  Article PubMed CAS Google Scholar
• Gerding DN: Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004, **38:**646–648.
  Article PubMed Google Scholar
• Pepin J, Saheb N, Coulombe MA, et al.: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, **41:**1254–1260.
  Article PubMed CAS Google Scholar
• Owens RC Jr, Donskey CJ, Gaynes RP, et al.: Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, **46:**S19–S31.
  Article PubMed Google Scholar
• Dallal RM, Harbrecht BG, Boujoukas AJ, et al.: Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, **235:**363–372.
  Article PubMed Google Scholar
• McEllistrem MC, Carman RJ, Gerding DN, et al.: A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005, **40:**265–272.
  Article PubMed Google Scholar
• McDonald LC, Killgore GE, Thompson A, et al.: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, **353:**2433–2441.
  Article PubMed CAS Google Scholar
• Rupnik M, Kato N, Grabnar M, Kato H: New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 2003, **41:**1118–1125.
  Article PubMed CAS Google Scholar
• Voth DE, Ballard JD: Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005, **18:**247–263.
  Article PubMed CAS Google Scholar
• Warny M, Pepin J, Fang A, et al.: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, **366:**1079–1084.
  Article PubMed CAS Google Scholar
• Wilcox MH, Fawley WN: Hospital disinfectants and spore formation by Clostridium difficile. Lancet 2000 **356:**1324.
  Article PubMed CAS Google Scholar
• Fawley WN, Underwood S, Freeman J, et al.: Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol 2007, **28:**920–925.
  Article PubMed Google Scholar
• Nash SV, Bourgeault R, Sands M: Colonic disease associated with a positive assay for Clostridium difficile toxin: a retrospective study. J Clin Gastroenterol 1997, **25:**476–479.
  Article PubMed CAS Google Scholar
• Nielsen ND, Layton BA, McDonald LC, et al.: Changing epidemiology of Clostridium difficile-associated disease: experience and perception of infectious diseases consultants. Infect Dis Clin Pract 2006, **14:**296–302.
  Article Google Scholar
• Lozniewski A, Rabaud C, Dotto E, et al.: Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol 2001, **39:**1996–1998.
  Article PubMed CAS Google Scholar
• Cloud J, Kelly CP: Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 2007, **23:**4–9.
  PubMed Google Scholar
• Gerding DN: New definitions will help, but cultures are critical for resolving unanswered questions about Clostridium difficile. Infect Control Hosp Epidemiol 2007, **28:**113–115.
  Article PubMed Google Scholar
• Clabots CR, Gerding SJ, Olson MM, et al.: Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure. J Clin Microbiol 1989, **27:**2386–2387.
  PubMed CAS Google Scholar
• Gerding DN, Muto CA, Owens RC Jr: Treatment of Clostridium difficile infection. Clin Infect Dis 2008, **46:**S32–S42.
  Article PubMed CAS Google Scholar
• Freeman J, Wilcox MH: The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol 2003, **56:**126–128.
  Article PubMed CAS Google Scholar
• Kamiya S, Yamakawa K, Ogura H, Nakamura S: Recovery of spores of Clostridium difficile altered by heat or alkali. J Med Microbiol 1989, **28:**217–221.
  Article PubMed CAS Google Scholar
• Rutala WA, Weber DJ: Uses of inorganic hypochlorite (bleach) in health-care facilities. Clin Microbiol Rev 1997, **10:**597–610.
  PubMed CAS Google Scholar
• Mayfield JL, Leet T, Miller J, Mundy LM: Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000, **31:**995–1000.
  Article PubMed CAS Google Scholar
• Carling PC, Parry MF, Von Beheren SM: Identifying opportunities to enhance environmental cleaning in 23 acute care hospitals. Infect Control Hosp Epidemiol 2008, **29:**1–7.
  Article PubMed CAS Google Scholar
• Dellit TH, Owens RC, McGowan JE Jr, et al.: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, **44:**159–177.
  Article PubMed Google Scholar
• Muto CA, Blank MK, Marsh JW, et al.: Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis 2007, **45:**1266–1273.
  Article PubMed Google Scholar
• Donskey CJ, Chowdhry TK, Hecker MT, et al.: Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000, **343:**1925–1932.
  Article PubMed CAS Google Scholar
• Lautenbach E, LaRosa LA, Marr AM, et al.: Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003, **36:**440–446.
  Article PubMed CAS Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, **45:**302–307.
  Article PubMed CAS Google Scholar
• Fekety R, Silva J, Kauffman C, et al.: Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989, **86:**15–19.
  Article PubMed CAS Google Scholar
• McFarland LV, Elmer GW, Surawicz CM: Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, **97:**1769–1775.
  Article PubMed CAS Google Scholar
• Musher DM, Logan N, Hamill RJ, et al.: Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006, **43:**421–427.
  Article PubMed CAS Google Scholar
• Louie TJ: Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options. Clin Infect Dis 2006, **42:**765–767.
  Article PubMed Google Scholar
• Hecht DW, Galang MA, Sambol SP, et al.: In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007, **51:**2716–2719.
  Article PubMed CAS Google Scholar
• Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE: Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 2006, **40:**2155–2163.
  Article PubMed CAS Google Scholar
• Ackermann G, Loffler B, Adler D, Rodloff AC: In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004, **48:**2280–2282.
  Article PubMed CAS Google Scholar
• Jodlowski TZ, Oehler R, Kam LW, Melnychuk I: Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother 2006, **40:**2164–2169.
  Article PubMed CAS Google Scholar
• Louie TJ, Peppe J, Watt CK, et al.: Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006, **43:**411–420.
  Article PubMed CAS Google Scholar
• Babcock GJ, Broering TJ, Hernandez HJ, et al.: Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006, **74:**6339–6347.
  Article PubMed CAS Google Scholar
• Sougioultzis S, Kyne L, Drudy D, et al.: Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005, **128:**764–770.
  Article PubMed Google Scholar